340B Provider Ally Stabenow Will Not Seek Re-Election to U.S. Senate in 2024

Sen. Debbie Stabenow (D-MI) headshot
U.S. Sen. Debbie Stabenow (D-Mich.) will not seek re-election in 2024, depriving 340B covered entities of a reliable ally.

U.S. Sen. Debbie Stabenow (D-Mich.) will not seek re-election in 2024, a decision that will deprive 340B covered entities of a reliable ally in Congress.

Stabenow issued a statement yesterday announcing her decision. She was one of six senators—three

Read More »

House GOP Leadership Spat Stymies All Action, Including Any on 340B

Rep. Kevin McCarthy (R-CA) pictured at the entrance to the West Wing of the White House
The split among House Republicans about whether to pick Rep. Kevin McCarthy (Calif.) to be House Speaker has ground the chamber to a halt.

The U.S. House was frozen stuck this morning after the new Republican majority splintered yesterday, the first day of the 118th Congress, over who should be the next House speaker.

Representatives cannot be sworn in and the House cannot begin

Read More »

Office of Pharmacy Affairs Get Slight Funding Bump

HRSA building and signage
HRSA plans to host a webinar for federal grantees in the days leading up to the 2024 340B recertification period.

President Biden on Dec. 29 signed a $1.7 trillion omnibus appropriations bill for fiscal year 2023 that gave the 340B drug pricing program a slight funding boost.

The U.S. Health Resources and Services Administration’s Office of Pharmacy Affairs will get

Read More »

Breaking: Congress Wants HRSA Briefing on Action to Safeguard 340B Entities’ “Lawful Access to Discounted Drugs”

Senate Appropriations committee room
The U.S. Senate Appropriations Committee released an omnibus FY 2023 spending bill late yesterday with report language requesting a HRSA briefing on its actions to safeguard providers' access to 340B drug discounts.

U.S. House and Senate appropriations committees want federal healthcare officials to brief them by April “on actions taken to safeguard covered entities’ lawful access to discounted drugs” under the 340B program.

The directive to the Health Resources and Services Administration

Read More »

117th Congress Nears End With No 340B Contract Pharmacy Fix Expected

U.S. Capitol building at sunrise
Five congressional Democrats signed on as co-sponsors to a bill that would bar drugmaker restrictions on 340B contract pharmacy arrangements.

The 117th Congress appears destined to end without further action on the 340B program.

The House and Senate are on track to finish all work for the year by no later than Friday, Dec. 23. According to news reports yesterday,

Read More »

Michigan Senate Rejects Attempt to Weaken Recent 340B Anti-Discrimination Law

Michigan Senate chamber
A bill that would enact contract pharmacy protections in Michigan has garnered renewed attention from 340B supporters and critics, alike, in the final days before the state’s legislature is set to recess for the summer.

The Michigan Senate has defeated legislation that hospitals say would have removed language from a nearly year-old state law that stops payers, pharmacy benefit managers, or other third parties from requiring 340B claims modifiers except as required to prevent Medicaid

Read More »

340B’s Critics Often Misunderstand its Intent, Ex-House E&C Chair Waxman Says in Health Affairs Commentary

Henry Waxman headshot
Ex-U.S. Rep. Henry Waxman (D-Calif.) says in a Health Affairs commentary that criticism of the drug discount program often “reflect[s] a misunderstanding of Congress’ intent.”

Henry Waxman, a California Democrat who was one of the original sponsors of the 340B law when it was created in 1992, says in a commentary in Health Affairs that criticism of the drug discount program often “reflect[s] a misunderstanding

Read More »

340B Report Publisher and CEO Slafsky: Expect More Attention to 340B in New Congress

U.S. Capitol building East elevation
Be prepared for a lot more attention on the 340B program in the upcoming Congress, 340B Report Publisher and CEO Ted Slafsky predicts.

Be prepared for a lot more attention on the 340B program in the upcoming Congress, 340B Report Publisher and CEO Ted Slafsky says in his latest column for medication management solutions company Omnicell.

340B was a hot topic in Congress

Read More »

Senior U.S. House Democrat and Republican Say They’re Hopeful Congress Will Act on 340B; Hearings Expected in New Congress

Rep. Robin Kelly (D-IL) and Rep. Brett Guthrie (R-KY) headshots
U.S. Reps. Robin Kelly (D-Ill.) and Brett Guthrie (R-Ky.) each said during an event yesterday they were hopeful Congress would act on 340B—Kelly regarding covered entities' concerns and Guthrie regarding those of payers and manufacturers.

The Democratic vice chair of the U.S. House Energy & Commerce Committee said during a media event yesterday she hopes Congress will address healthcare providers’ concerns about the 340B program during its lame duck session scheduled to end Dec. 15.

Read More »

Mike Braun, Key U.S. Senator on 340B Matters, Won’t See Re-Election in 2024

Sen. Mike Braun (R-IN) headshot
U.S. Sen. Mike Braun (R-Ind.), a key voice on 340B matters, is running for governor of Indiana in 2024 instead of seeking re-election to Congress.

U.S. Sen. Mike Braun (R-Ind.), whom 340B covered entities have considered both a friend and foe, has decided to run for governor of Indiana in 2024 rather than seek reelection to the Senate.

A senator since 2019, Braun serves on

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live